Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan

2016 ◽  
Vol 27 (5) ◽  
pp. 755-765 ◽  
Author(s):  
Tsuneyo Mimori ◽  
Masayoshi Harigai ◽  
Tatsuya Atsumi ◽  
Takao Fujii ◽  
Masataka Kuwana ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interim Analysis ◽  
Antirheumatic Drug ◽  
Surveillance Study ◽  
Oral Disease ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Disease Modifying ◽  
Disease Modifying Antirheumatic Drug

scholarly journals Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis

2021 ◽  
Author(s):  
Małgorzata Łączna ◽  
Damian Malinowski ◽  
Agnieszka Paradowska-Gorycka ◽  
Krzysztof Safranow ◽  
Violetta Dziedziejko ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Antirheumatic Drug ◽  
Disease Modifying ◽  
Individual Disease ◽  
Disease Modifying Antirheumatic Drug

Abstract Aim Leflunomide is a disease-modifying antirheumatic drug used in therapy for rheumatoid arthritis (RA). Previous studies indicated that oestrogens and androgens may affect the response to leflunomide in RA patients. The synthesis of androgens is regulated by cytochrome CYB5A. The aim of this study was to examine the association between the CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with RA. Methods The study included 111 women diagnosed with RA. Leflunomide was administered in monotherapy at a dose of 20 mg/day. All patients underwent a monthly evaluation for 12 months after the initiation of treatment with leflunomide. Results After 12 months of therapy, the changes in individual disease activity parameters, such as: DAS28, ESR, CRP and VAS, were not statistically significantly different between rs1790834 genotypes in the Kruskal–Wallis test. Conclusions The results of our study suggest lack of statistically significant association between the CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with RA.

scholarly journals Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

2017 ◽  
Vol 69 (3) ◽  
pp. 506-517 ◽  
Author(s):  
Roy Fleischmann ◽  
Michael Schiff ◽  
Désirée van der Heijde ◽  
Cesar Ramos-Remus ◽  
Alberto Spindler ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Treatment ◽  
Antirheumatic Drug ◽  
Disease Modifying ◽  
Disease Modifying Antirheumatic Drug
Sign in / Sign up

Export Citation Format

Share Document